Literature DB >> 1107224

Effects of BCG, Corynebacterium parvum, and methanol-extration residue in the reduction of mortality from Staphylococcus aureus and Candida albicans infections in immunosuppressed mice.

N A Sher, S D Chaparas, L E Greenberg, S Bernard.   

Abstract

An immunosuppressed mouse model was devised to test the effects of immunopotentiators on the prevention of bacterial and fungal infections. The effects of BCG and Corynebacterium were tested against Staphylococcus aureus and Candida albicans infection. The effect of methanol-extraction residue (MER-BCG) was tested against S. aureus septicemia. CDF mice were given various doses of BCG, 1.0 mg of C. parvum, or 0.5 mg of MER intraperitoneally at varying intervals before injection of an intravenous bacterial challenge. Four days before challenge, 300 mg of cyclophosphamide per ml was given intraperitoneally. BCG (106 colony-forming units) reduced mortality due to S.aureus at pretreatment intervals of 3, 7, 14, and 28 days. Isonicotinic acid hydrazide treatment elimated the protective effect of the live BCG. C. parvum was as effective as BCG against S. aureus septicemia when given 3 days before infection, but lost most of its protective effect after that time. MER protected at doses as small as 0.25 mg when given 25 days prior to challenge. Both BCG and C. parvum exerted a protective effect against Candida albicans infection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1107224      PMCID: PMC415439          DOI: 10.1128/iai.12.6.1325-1330.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  [STIMULATION OF THE PHAGOCYTIC ACTIVITY OF THE RETICULOENDOTHELIAL SYSTEM BY CORYNEBACTERIUM PARVUM].

Authors:  B N HALPERN; A R PREVOT; G BIOZZI; C STIFFEL; D MOUTON; J C MORARD; Y BOUTHILLIER; C DECREUSEFOND
Journal:  J Reticuloendothel Soc       Date:  1964-01

2.  Differential effects of cyclophosphamide on the B and T cell compartments of adult mice.

Authors:  G D Stockman; L R Heim; M A South; J J Trentin
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

3.  Immunotherapy for acute myelogenous leukaemia.

Authors:  R Powles
Journal:  Br J Cancer Suppl       Date:  1973-08

Review 4.  Cellular hypersensitivity and cellular immunity in the pathogensis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes.

Authors:  A M Dannenberg
Journal:  Bacteriol Rev       Date:  1968-06

5.  The host response to Calmette-Guérin bacillus infection in mice.

Authors:  R V Blanden; M J Lefford; G B Mackaness
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

6.  Comparative effect of two strains of C. parvum on phagocytic activity and tumour growth.

Authors:  L H Smith; M F Woodruff
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

7.  [Response of the RES to Mycobacterium tuberculosis (BCG) and Corynebacterium parvum in mice of different strains].

Authors:  C Stiffel; D Mouton; Y Bouthillier; C Decreusefond; G Biozzi
Journal:  J Reticuloendothel Soc       Date:  1970-02

8.  Chemotherapy of spontaneous leukemia in germfree AKR mice.

Authors:  M Pollard; N Sharon
Journal:  J Natl Cancer Inst       Date:  1970-10       Impact factor: 13.506

9.  Fatal infections in childhood leukemia.

Authors:  W T Hughes
Journal:  Am J Dis Child       Date:  1971-10

10.  Salmonellosis in Mice Infected with Mycobacterium bovis BCG II. Resistance to Infection.

Authors:  V C Senterfitt; J W Shands
Journal:  Infect Immun       Date:  1970-06       Impact factor: 3.441

View more
  20 in total

1.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  The effect of BCG-vaccination on vaccinia virus infections in mice.

Authors:  G T Werner
Journal:  Experientia       Date:  1979-11-15

3.  A role for immune stimulation in the treatment of microbial infections?

Authors:  J Drews
Journal:  Infection       Date:  1980       Impact factor: 3.553

4.  Trapping and killing of Candida albicans by Corynebacterium parvum-activated livers.

Authors:  R T Sawyer; R J Moon; E S Beneke
Journal:  Infect Immun       Date:  1981-05       Impact factor: 3.441

5.  Influence of PSK (Krestin) on resistance to infection of Pseudomonas aeruginosa in tumor-bearing mice.

Authors:  T Ando; I Motokawa; K Sakurai; Y Ohmura; T Fujii; K Matsunaga; C Yoshikumi; K Nomoto
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Increased bone marrow production of granulocytes and mononuclear phagocytes induced by mycobacterial adjuvants: improved recovery of leukopoiesis in mice after cyclophosphamide treatment.

Authors:  W C Buhles; M Shifrine
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

7.  Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leukemic mice.

Authors:  N R Di Luzio; D L Williams
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

8.  Fate of Legionella pneumophila Philadelphia-1 strain in resident, elicited, activated, and immune peritoneal macrophages of guinea pigs.

Authors:  S Yoshida; Y Mizuguchi; Y Nikaido; M Mitsuyama; K Nomoto
Journal:  Infect Immun       Date:  1987-10       Impact factor: 3.441

9.  Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.

Authors:  E B Fraser-Smith; T R Matthews
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

10.  Comparative effects of carrageenan on systemic candidiasis and listeriosis in mice.

Authors:  B Hurtrel; P H Lagrange
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.